
From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption
John Berdahl, MD, is with Vance Thompson Vision in Sioux Falls, South Dakota.
From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption
Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.
John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.
Crosslinking meets the previously unmet needs of progressive keratoconus patients and provides an opportunity to increase engagement with optometrists, explain John Berdahl, MD, and George O. Waring IV, MD.
Though much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
Published: April 24th 2025 | Updated:
Published: April 24th 2025 | Updated:
Published: February 7th 2025 | Updated:
Published: January 1st 2017 | Updated:
Published: October 15th 2017 | Updated: